Menarini strengthens its presence in aesthetic dermatology in India
Menarini India Private Limited (‘Menarini India’), part of the Menarini Group, the world’s largest Italian biopharmaceutical company and a global...
Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...
Insights From HumanFirst Show Breadth of Pharmaceutical Investment in AI/ML and Digital Endpoints in Clinical Trials
Regulators are increasingly approving AI-powered endpoints using digital health technologies (DHTs) in drug development. To quantify this trend, HumanFirst, life...
Empowering Pharmaceutical Companies in Chronic Disease Research and Identifying Unmet Needs says Disease Landscape Insights
Chronic diseases are long term ailments that progress over time. They are non-communicable in nature and can lead to severe...
WuXi Vaccines Launches Its First Vaccines CDMO Site in China
WuXi Vaccines, a leading contract development and manufacturing organization (CDMO) focused on vaccine discovery, development, and manufacturing, has launched its...
MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, is the first CTDMO (contract testing, development...
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that on September 19, 2023,...
Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC
Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab injection),...
‘LEQEMBI® Intravenous Infusion’ approved for the treatment of Alzheimer’s disease in Japan
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that "LEQEMBI® Intravenous Infusion" (200 mg, 500mg, lecanemab) has...
Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology
Pierre Fabre Laboratories and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a...
